Fifth Third Bancorp
NRIX icon

Fifth Third Bancorp’s Nurix Therapeutics NRIX Stock Holding History

Fifth Third Bancorp’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.29K Sell
218
-30
-12% -$511 ﹤0.01% 3912
2026
Q1 		$3.85K Buy
+248
New +$4.11K ﹤0.01% 3924

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fifth Third Bancorp's NRIX Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Nurix Therapeutics (NRIX) stake by 12% in Q2 2026, selling an estimated $511 and leaving 218 shares worth $5.29K. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

Fifth Third Bancorp first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Fifth Third Bancorp held 218 shares of Nurix Therapeutics worth $5.29K as of Q2 2026.
  • Fifth Third Bancorp sold 30 Nurix Therapeutics shares in Q2 2026, an estimated $511.
  • Nurix Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3912 holding.
  • Fifth Third Bancorp first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.